MASSY, FRANCE--(Marketwire - October 18, 2012) - Quantum Genomics (NYSE Euronext Paris: MLQGC) announces today the successful
completion of the first-in-human phase I clinical study with its product
QGC001 is the first of a new class of drugs that aim to treat high
pressure through an inhibition of the aminopeptidase A enzyme (APA) at the
The results of this phase Ia study conducted in 56 healthy male
randomized in 8 sequential groups (10 mg, 50 mg, 125 mg, 250 mg, 500 mg,
1000 mg and 1250 mg) show that QGC001 is safe and well-tolerated
single oral administration. Pharmacokinetic analysis demonstrated good
proportional exposure to QGC001.
Lionel Segard, CEO of Quantum Genomics says: « The results of
clinical study are very encouraging. All doses tested have been
A multiple ascending dose phase Ib study is underway and if successful,
to start phase II studies in hypertensive patients next year ».
About QGC001 and arterial hypertension
QGC001 is the first molecule of a new class of anti-hypertensive agents,
aminopeptidase A inhibitors (BAPAI), which were co-discovered by the
teams of Dr. C. Llorens-Cortes (INSERM U1050/Collège de France) and
Roques (INSERM U1022/CNRS/Université Paris Descartes).
QGC001 could offer a therapeutic alternative for the treatment of high
pressure for patients with Low Renin High Vasopressin profile (LRHV) whose
blood pressure is often more difficult to control with conventional
the renin angiotensin system.
Arterial hypertension affects an estimated 1 billion people
million people in France). Despite the availability of many
drugs, 60% of patients diagnosed with hypertension are still poorly
by current medications for various reasons. Moreover, the overall
resistant hypertension to at least three antihypertensive drugs
diuretic) is estimatedto be 10% of the hypertensive population.
The world market for anti-hypertensive drugs is projected to exceed
billion by the year 2015. 
About Quantum Genomics
QGC is a biotechnology company developing new therapies in areas where an
medical need exists.
QGC is presently focused on the treatment of cardiovascular
especially arterial hypertension.
The company is co-developing its products with academic teams and will
strategic alliances and commercial partnerships with larger company in
bring them to market.
The company is headquartered in Massy (France) under the leadership of
Segard, supported by a management team of experienced people, including
Balavoine (VP Research & Development) and Michel Lepers (VP
 Global Industry Analysts, Inc 2010
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Quantum Genomics via Thomson Reuters ONE